# Charles River Laboratories International, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Charles River Laboratories International, Inc). ## Overview Charles River Laboratories International, Inc. is a contract research, development, and manufacturing services company that supports drug discovery and non-clinical development for biopharmaceutical and other life science customers. Founded in 1947 and headquartered in Wilmington, Massachusetts, it operates across early-stage research, safety assessment, and manufacturing support. The company’s model is built around outsourcing scientific work that customers do not want to perform fully in-house, especially in the preclinical phase of drug development. Its portfolio spans discovery services, laboratory models and research support, non-clinical safety testing, and selected manufacturing-related services. Charles River competes on scientific expertise, regulatory quality, responsiveness, and global delivery capabilities. It serves a broad customer base that includes large pharma, biotech, academic institutions, government agencies, and other commercial life science organizations. ## Products & services • Discovery services for early-stage drug research • Safety assessment and non-clinical development testing • Research models and related support services (RMS) • Microbial Solutions for contamination detection and control • Biologics Solutions and manufacturing support services • Contract research and contract manufacturing services • eCommerce, secure portals, and client data access tools - **Research Models and Services (RMS)** (28%) — Laboratory animal models, related research support, and services used in preclinical research workflows. - **Discovery and Safety Assessment (DSA)** (47%) — Discovery services and non-clinical safety testing that help customers advance drug candidates toward development. - **Manufacturing Support** (25%) — Microbial Solutions and biologics-related services that support quality control and biologics production workflows. - Discovery services for early-stage drug research - Safety assessment and non-clinical development testing - Research models and related support services (RMS) - Microbial Solutions for contamination detection and control - Biologics Solutions and manufacturing support services - Contract research and contract manufacturing services - eCommerce, secure portals, and client data access tools ## Customers Charles River sells primarily to biopharmaceutical companies that outsource early-stage research, safety testing, and selected manufacturing support rather than building all capabilities internally. It also serves biotechnology companies, including emerging and mid-sized firms that need flexible access to specialized scientific infrastructure. Additional customers include agricultural and industrial chemical companies, life science and veterinary medicine companies, medical device and diagnostic firms, consumer product companies, contract research organizations, and contract manufacturing organizations. Universities, teaching hospitals, government agencies, and non-governmental organizations also buy from the company, especially for research and testing services. Demand is tied to customers’ R&D budgets and development pipelines, so spending patterns in pharma and biotech directly affect Charles River’s volumes. - **Major biopharmaceutical companies** (primary) — Buy discovery, safety assessment, and manufacturing support to accelerate pipelines and reduce internal fixed costs. - **Biotechnology companies** (primary) — Use outsourced scientific capacity for early-stage research and non-clinical development, especially when internal infrastructure is limited. - **Contract research and manufacturing organizations** (secondary) — Purchase specialized services and support capabilities to complement their own outsourced development and production offerings. - **Academic, government, and non-profit research organizations** (secondary) — Buy research models, testing, and scientific services for research programs and regulated studies. - **Other life science and regulated product companies** (secondary) — Includes medical device, diagnostic, veterinary, agricultural, and consumer product customers that need testing and compliance-oriented support. - Large biopharmaceutical companies outsourcing preclinical work - Biotechnology companies needing flexible discovery and safety testing - Agricultural and industrial chemical companies with research programs - Medical device, diagnostic, and consumer product companies - Contract research and contract manufacturing organizations - Academic institutions, hospitals, government agencies, and NGOs ## Geography Charles River describes itself as having broad geographic availability with consistent quality, which matters because customers often want the same standards across multiple study locations. The company is headquartered in the United States, but it operates globally and explicitly references revenue and long-lived assets across the United States, Europe, Canada, Asia Pacific, and other countries. Its competitive set also spans the U.S., Europe, China, Canada, and Japan, showing that the business is embedded in a global outsourced R&D market. The company holds most of its cash outside the U.S., indicating meaningful non-U.S. operating exposure. Geography matters operationally because regulatory standards, customer proximity, and currency movements can affect utilization, pricing, and margins. - Headquartered in Wilmington, Massachusetts, United States - Operates across the United States, Europe, Canada, Asia Pacific, and other countries - Global delivery is part of the value proposition for multinational pharma clients - Non-U.S. cash holdings indicate substantial overseas operating presence - Currency movements can affect reported revenue and operating results - Competitive pressure comes from U.S., European, Chinese, Canadian, and Japanese rivals ## Strategy Charles River’s strategy is centered on being a preferred outsourced partner across the early drug discovery and non-clinical development chain. The company emphasizes scientific expertise, regulatory compliance, quality, responsiveness, and flexible solutions that can be scaled across client programs. It also seeks to deepen relationships with large biopharmaceutical customers through preferred provider arrangements and strategic partnerships that encourage cross-selling across the non-clinical portfolio. Management is also focused on disciplined capital allocation, including infrastructure investment, selective acquisitions and divestitures, and share repurchases. In the near term, the company is managing through cautious client spending and a softer demand environment in parts of DSA while supporting growth in RMS and Manufacturing. - **Grow preferred-provider relationships with large biopharma clients** (medium-term) — These relationships improve visibility, increase wallet share, and support recurring multi-service demand. - **Cross-sell across the non-clinical portfolio** (short-term) — Bundling discovery, safety, and manufacturing support increases customer stickiness and broadens revenue per client. - **Maintain disciplined capacity and capital spending** (short-term) — The business is capital intensive and must align infrastructure with demand to protect returns. - **Optimize portfolio through acquisitions and divestitures** (medium-term) — Portfolio actions can improve strategic focus and redeploy capital toward higher-value capabilities. - Expand outsourced early-stage drug discovery and non-clinical development work - Deepen relationships with large pharma and mid-tier biotech clients - Cross-sell across discovery, safety assessment, and manufacturing support - Maintain quality, compliance, and responsiveness as differentiators - Invest in infrastructure and capacity where demand supports growth - Use acquisitions, divestitures, and buybacks to shape the portfolio ## Risks Charles River is exposed to demand swings in pharmaceutical and biotechnology R&D, because its services are discretionary inputs to customers’ development budgets. The company also bears contract execution risk, including termination, scope reduction, underpricing, cost overruns, and delays, which can pressure margins in project-based work. Cybersecurity and confidentiality are important risks because the company handles sensitive study data and relies on third-party software and cloud infrastructure; a breach could damage customer trust and trigger legal or regulatory consequences. Competitive pressure is intense across all three segments, including in-house client capabilities and numerous global competitors in China, Europe, Canada, Japan, and the U.S. In addition, venture capital and strategic equity investments add earnings volatility through gains, losses, and impairments that are not tied to core operating performance. - **Cyclicality in pharma and biotech R&D spending** [high] — The company depends on customer budgets for outsourced discovery, testing, and manufacturing support, so lower R&D spending reduces volumes. - **Contract scope reduction, termination, and pricing pressure** [high] — Project-based contracts can be reduced or repriced, creating revenue and margin risk if utilization falls or costs are fixed. - **Cybersecurity and confidentiality breaches** [high] — The company stores sensitive client study data and relies on third-party IT infrastructure, so a breach could cause legal, reputational, and commercial harm. - **Competitive intensity from global CROs and in-house capabilities** [medium] — Customers can shift work to internal labs or alternative providers, pressuring pricing and utilization. - **Investment losses and impairments from venture capital portfolio** [medium] — Non-operating investment marks can materially affect net income even when core operations are stable. - Customer R&D spending cuts can reduce demand for outsourced research and testing - Contracts may be terminated, reduced, underpriced, or delayed - Cybersecurity incidents could compromise confidential study data and client trust - Strong competition from in-house teams and global CRO/manufacturing rivals - Foreign exchange and global operating complexity can affect margins - Venture capital and strategic equity investments can create earnings volatility ## Accounting Revenue recognition is a critical accounting area because Charles River provides a mix of services and manufacturing support that may be recognized over time based on performance obligations, milestones, or completed work. The company’s results can also be affected by quarterly volatility in client demand, project timing, and foreign currency movements, which makes period-to-period comparisons less linear than in subscription businesses. Goodwill and intangible assets are important because the company has grown through acquisitions and reports amortization of intangible assets in segment results, so impairment or amortization assumptions can materially affect earnings. The company also uses estimates for contingent consideration, credit losses, and other liabilities, which can move with changes in customer activity and acquisition outcomes. Finally, venture capital and strategic equity investments introduce fair value measurement and impairment judgments that can create significant non-operating volatility. - **Revenue recognition for services and manufacturing support** — Can shift revenue between quarters and affect reported growth - **Goodwill and intangible asset amortization/impairment** — Can materially affect operating income and equity - **Contingent consideration** — Can create earnings volatility and cash outflows - **Venture capital and strategic equity investments** — Can materially affect other income/expense and net income - **Allowance for credit losses** — Affects operating expenses and receivables valuation - Revenue recognition depends on service completion, milestones, and contract terms - Quarterly revenue can fluctuate with study timing, customer spending, and FX - Acquisition-related intangible assets create amortization and impairment risk - Contingent consideration requires judgment and can change with acquisition outcomes - Credit loss estimates matter because client demand and payment behavior can weaken - Fair value marks on venture investments can swing non-operating earnings --- *Last updated: 2026-09-24T11:29:20.392732+00:00*